KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
11.93
-0.41 (-3.32%)
At close: Mar 28, 2025, 4:00 PM
12.06
+0.13 (1.11%)
After-hours: Mar 28, 2025, 6:02 PM EDT
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for KalVista Pharmaceuticals stock have an average target of 24.83, with a low estimate of 19 and a high estimate of 30. The average target predicts an increase of 108.13% from the current stock price of 11.93.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 5 | 5 | 5 |
| Buy | 1 | 1 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 6 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +134.70% | Mar 26, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $19 | Buy | Reiterates | $19 | +59.26% | Mar 26, 2025 |
| Jones Trading | Jones Trading | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +151.47% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +67.64% | Mar 14, 2025 |
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +134.70% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
46.86M
EPS This Year
-3.60
from -3.44
EPS Next Year
-3.07
from -3.60
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 89.5M | 202.2M | ||
| Avg | n/a | 46.9M | 151.6M | ||
| Low | n/a | 17.8M | 108.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 331.6% | ||
| Avg | - | - | 223.5% | ||
| Low | - | - | 131.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.51 | -2.53 | -1.04 | ||
| Avg | -3.60 | -3.07 | -1.62 | ||
| Low | -3.59 | -3.68 | -2.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.